Salud financiera de hoja de balance de Allakos
Salud financiera controles de criterios 6/6
Allakos tiene unos fondos propios totales de $221.0M y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $283.5M y $62.5M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$170.79m |
| Patrimonio | US$168.82m |
| Total pasivo | US$74.79m |
| Activos totales | US$243.61m |
Actualizaciones recientes sobre salud financiera
We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
Dec 01
Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth
Aug 03Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Apr 20Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Aug 06Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?
Apr 22We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
Dec 01Recent updates
We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
Dec 01Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth
Aug 03Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Apr 20Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 04Allakos: Potential For Comeback With Lirentelimab With 2 Indications
Oct 18Allakos prices ~$150M underwritten offering
Sep 19Allakos falls as lead asset offers mixed results in late-stage trial
Sep 09Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Aug 06Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?
Apr 22Allakos: Sad End To A Promising Asset
Dec 23We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
Dec 01We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth
Aug 16Allakos: Upcoming Phase 3 Data Makes The Stock Interesting
Aug 06Allakos provides lirentelimab clinical trial enrollment updates, names new CMO
Jun 07We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
May 02Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?
Mar 10Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling
Jan 28
We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow
Dec 07Allakos EPS misses by $0.02
Nov 09Análisis de la situación financiera
Pasivos a corto plazo: ALLKLos activos a corto plazo ($218.3M) de la empresa superan a sus pasivos a corto plazo ($23.5M).
Pasivo a largo plazo: ALLKLos activos a corto plazo ($218.3M) superan a sus pasivos a largo plazo ($39.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ALLK está libre de deudas.
Reducción de la deuda: ALLK no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ALLK tiene suficiente margen de tesorería para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: ALLK dispone de suficiente liquidez para 1.3 años si el flujo de caja libre sigue reduciéndose al ritmo histórico de 33.6% cada año.